Musculoskeletal Pain Market Report 2026-2036: Growth Drivers, Epidemiology, Key Unmet Needs, Growth Forecast
The report provides a comprehensive assessment of the musculoskeletal pain market across the seven major markets: the United States, Germany, France, Italy, Spain, the United Kingdom, and Japan. It examines historical and forecast epidemiology, treatment practices, market dynamics, competitive activity, patient burden, drug uptake, pricing, reimbursement, and commercial opportunities from 2022 through 2036.
Musculoskeletal conditions affect approximately 1.7 billion people worldwide and remain the leading cause of disability. Low back pain contributes the greatest number of years lived with disability, while osteoarthritis, chronic neck pain, rheumatoid arthritis, fibromyalgia, and other degenerative or inflammatory disorders create substantial clinical and economic burdens. In the United States, musculoskeletal pain is estimated to affect nearly 37% of the population.
Musculoskeletal Pain Market Growth Drivers
The musculoskeletal pain market is expected to expand steadily through 2036, supported by population aging, increasing osteoarthritis prevalence, obesity, sedentary lifestyles, occupational risk factors, and rising demand for long-term pain management. Greater awareness of opioid-related dependence, overdose, and safety concerns is also accelerating the shift toward non-opioid analgesics, localized treatments, regenerative medicine, and potential disease-modifying therapies.
Current treatments primarily control symptoms and generally have limited effects on disease progression. This creates significant opportunities for therapies that can deliver durable pain relief, improve physical function, reduce treatment frequency, and slow structural deterioration. Products with differentiated mechanisms, localized delivery, favorable safety profiles, or extended duration of benefit may secure meaningful competitive advantages.
Current Musculoskeletal Pain Treatment Landscape
Musculoskeletal pain management follows a multimodal, stepwise approach based on the underlying condition, pain severity, functional impairment, comorbidities, and patient characteristics. Exercise therapy, physiotherapy, patient education, weight management, manual therapy, and psychosocial interventions remain central to long-term care.
Nonsteroidal anti-inflammatory drugs continue to be widely used because of their analgesic and anti-inflammatory effects. Topical formulations are increasingly recommended for localized knee and hand osteoarthritis because they can reduce systemic exposure. Acetaminophen may be used for mild pain, although its effectiveness is limited in inflammatory conditions. Opioids are generally reserved for severe acute pain or refractory cases because of dependence risks and limited long-term benefits.
Intra-articular corticosteroids, viscosupplements, nerve blocks, and image-guided procedures may provide relief for selected patients. Joint replacement, spinal decompression, and other surgical procedures are typically considered for advanced disease or cases that do not respond adequately to conservative management.
Diagnosis is based on medical history, physical examination, functional assessment, imaging, and laboratory testing when inflammatory or autoimmune disease is suspected. X-ray, magnetic resonance imaging, computed tomography, and ultrasonography support the identification of degenerative, structural, inflammatory, soft-tissue, and neurological abnormalities.
Key Unmet Needs in Musculoskeletal Pain
- Limited availability of disease-modifying or curative therapies Persistent burden of chronic and recurrent pain Safety limitations associated with long-term pharmacological treatment Need for durable functional and structural improvement Insufficient biomarkers and patient-stratification tools Variable access, reimbursement, adherence, and treatment outcomes
Approved Musculoskeletal Pain Therapies
ZILRETTA, an extended-release formulation of triamcinolone acetonide developed by Flexion, is approved for osteoarthritis knee pain. Its microsphere-based formulation enables sustained intra-articular exposure and longer symptom control than conventional corticosteroid injections. The therapy received US Food and Drug Administration approval in October 2017 following Phase III results demonstrating significant improvements in knee pain. ZILRETTA generated USD 116.6 million in 2025 sales, reflecting continued demand for localized, non-opioid pain management.
LOQOA TAPE, developed by Taisho Pharmaceutical and TOKUHON Corporation, is a transdermal S-flurbiprofen and mentha oil formulation approved in Japan for osteoarthritis pain and inflammation. The product received Japanese approval in September 2015 and launched in January 2016. Its localized delivery supports continued use within Japan's osteoarthritis treatment market.
Viscosupplementation products, including DUROLANE and Synvisc-One, also maintain an established market presence. Single-injection regimens and longer-lasting benefits may offer convenience and economic advantages over products requiring multiple administrations.
Musculoskeletal Pain Pipeline and Emerging Therapies
The musculoskeletal pain pipeline is shifting toward non-opioid analgesics, regenerative treatments, long-acting intra-articular therapies, and disease-modifying osteoarthritis drug candidates. Stem cell-based therapies, monoclonal antibodies, novel small molecules, and sustained-release formulations are being evaluated for their potential to improve symptoms while addressing structural disease progression.
Mesoblast is developing rexlemestrocel-L for chronic low back pain associated with disc degeneration. The regenerative therapy is intended for patients who have exhausted conservative options and may otherwise require invasive surgery. In April 2026, Mesoblast outlined development milestones that included pivotal enrollment completion, top-line data anticipated in 2027, a planned Biologics License Application submission, and a potential US launch subject to successful clinical and regulatory outcomes.
Taiwan Liposome Company is evaluating TLC599, a sustained-release dexamethasone sodium phosphate formulation, in Phase III development for knee osteoarthritis. The therapy is designed to provide rapid and prolonged pain control following local administration. In April 2026, the company presented exploratory structural-benefit data at the OARSI World Congress, supporting continued investigation of TLC599 as a potential disease-modifying osteoarthritis therapy.
Biosplice Therapeutics announced in January 2026 that it had submitted a New Drug Application to the FDA for lorecivivint in knee osteoarthritis. Other companies active in the musculoskeletal pain competitive landscape include Centrexion Therapeutics, Flexion, Taisho Toyama Pharmaceutical, Mesoblast, Taiwan Liposome Company, and additional established and emerging developers.
Musculoskeletal Pain Market Outlook
The future musculoskeletal pain treatment landscape is expected to favor therapies that reduce reliance on opioids, offer fewer administrations, extend the duration of pain relief, and improve mobility and quality of life. Regenerative treatments and disease-modifying candidates could reshape care in knee osteoarthritis and chronic low back pain, where existing therapies remain predominantly symptom-focused.
The report evaluates therapy-level market share, peak patient share, adoption rates, sales potential, pricing, reimbursement, and market access across the seven major markets. It also assesses clinical trial activity, regulatory developments, patents, strategic partnerships, mechanisms of action, and competitive positioning for approved and investigational therapies.
Report Coverage and Strategic Value
- Musculoskeletal pain epidemiology and patient population forecasts Historical and forecast market analysis from 2022 through 2036 Current treatment practices and evolving therapeutic algorithms Approved therapy profiles and Phase I-III pipeline analysis Drug uptake, peak patient share, pricing, and reimbursement trends Competitive intelligence and company-level market assessment Unmet needs, market attractiveness, and commercial opportunities SWOT and conjoint analysis of current and emerging therapies Country-level insights from key opinion leaders and clinical experts
Insights from more than 10 key opinion leaders and subject-matter experts support the report's assessment of real-world prescribing, patient adherence, treatment switching, market access, epidemiology, and future drug adoption. The findings are designed to help pharmaceutical companies, investors, healthcare organizations, and other stakeholders develop evidence-based clinical, commercial, market-access, and portfolio strategies within the global musculoskeletal pain therapeutics market.
Key Topics Covered
1. Key Insights
2. Report Introduction
3. Executive Summary of Musculoskeletal Pain
4. Key Events
4.1. Upcoming Key Catalysts
4.2. Key Conferences And Meetings
4.3. Key Transactions And Collaborations
4.4. News Flow
5. Epidemiology and Market Forecast Methodology of Musculoskeletal Pain
6. Musculoskeletal Pain Market Overview at a Glance
6.1. Market Share (%) Distribution of Musculoskeletal Pain in 2025
6.2. Market Share (%) Distribution of Musculoskeletal Pain in 2036
7. Disease Background and Overview of Musculoskeletal Pain
7.1. Introduction
7.2. Types of Musculoskeletal Pain
7.3. Signs and Symptoms of Musculoskeletal Pain
7.4. Causes of Musculoskeletal Pain
7.5. Pathophysiology of Musculoskeletal Pain
7.6. Diagnosis of Musculoskeletal Pain
7.7. Biomarkers for Musculoskeletal Pain
8. Treatment of Musculoskeletal Pain
8.1. Guidelines for Management for Musculoskeletal pain
9. Epidemiology and Patient Population of Musculoskeletal Pain
9.1. Key Findings
9.2. Assumptions and Rationale: The 7MM
9.2.1. Total Diagnosed Prevalent cases of Musculoskeletal Pain
9.3. The United States
9.3.1. Musculoskeletal Pain Diagnosed Prevalent Cases in the United States
9.3.2. Musculoskeletal Pain Age-specific Cases in the United States
9.3.3. Musculoskeletal Pain Gender-specific Cases in the United States
9.3.4. Musculoskeletal Pain Total Treated Cases in the United States
9.4. EU4 and the UK
9.4.1. Musculoskeletal Pain Diagnosed Prevalent Cases in EU4 and the UK
9.4.2. Musculoskeletal Pain Age-specific Cases in EU4 and the UK
9.4.3. Musculoskeletal Pain Gender-specific Cases in EU4 and the UK
9.4.4. Musculoskeletal Pain Total Treated Cases in EU4 and the UK
9.5. Japan
9.5.1. Musculoskeletal Pain Diagnosed Prevalent Cases in Japan
9.5.2. Musculoskeletal Pain Age-specific Cases in Japan
9.5.3. Musculoskeletal Pain Gender-specific Cases in Japan
9.5.4. Musculoskeletal Pain Total Treated Cases in Japan
10. Patient Journey of Musculoskeletal Pain
11. Marketed Therapies of Musculoskeletal Pain
11.1. Marketed Competitive Landscape of Musculoskeletal Pain
11.2. ZILRETTA: Flexion Therapeutics
11.2.1. Product Description
11.2.2. Regulatory Milestones
11.2.3. Other Development Activities
11.2.4. Summary of Pivotal Trials
11.2.5. Analyst's Views
11.3. LOQOA TAPE: Taisho Pharmaceutical
11.3.1. Product Description
11.3.2. Regulatory Milestones
11.3.3. Other Development Activities
11.3.4. Summary of Pivotal Trials
11.3.5. Analyst's Views
List to be continued in report.
12. Emerging Therapies of Musculoskeletal Pain
12.1. Emerging Competitive Landscape of Musculoskeletal Pain
12.2. Rexlemestrocel-L (MPC-06-ID): Mesoblast
12.2.1. Product Description
12.2.2. Other Developmental Activities
12.2.3. Clinical Development
12.2.4. Safety and Efficacy
12.2.5. Analyst's Views
12.3. TLC599: Taiwan Liposome Company
12.3.1. Product Description
12.3.2. Other Developmental Activities
12.3.3. Clinical Development
12.3.4. Safety and Efficacy
12.3.5. Analyst's Views
List to be continued in the report.
13. Musculoskeletal Pain: 7MM Analysis
13.1. Key Findings
13.2. Market Outlook
13.3. Conjoint Analysis
13.4. Key Market Forecast Assumptions
13.4.1. Cost Assumptions and Rebate
13.4.2. Pricing Trends
13.4.3. Analogue Assessment
13.4.4. Launch Year and Therapy Uptake
13.5. Total Market Size of Musculoskeletal Pain in the 7MM
13.6. The United States
13.6.1. Total Market Size of Musculoskeletal Pain in the United States
13.6.2. Market Size of Musculoskeletal Pain by Therapies in the United States
13.7. EU4 and the UK
13.7.1. Total Market Size of Musculoskeletal Pain in EU4 and the UK
13.7.2. Market Size of Musculoskeletal Pain by Therapies in EU4 and the UK
13.8. Japan
13.8.1. Total Market Size of Musculoskeletal Pain in Japan
13.8.2. Market Size of Musculoskeletal Pain by Therapies in Japan
14. Unmet Needs of Musculoskeletal Pain
15. SWOT Analysis of Musculoskeletal Pain
16. KOL Views of Musculoskeletal Pain
17. Market Access and Reimbursement
17.1. United States
17.1.1. Centre for Medicare & Medicaid Services (CMS)
17.2. EU4 and the UK
17.2.1. Germany
17.2.2. France
17.2.3. Italy
17.2.4. Spain
17.2.5. United Kingdom
17.3. Japan
17.4. Summary and Comparison of Market Access and Pricing Policy Developments in 2025
17.5. Musculoskeletal Pain: Market Access and Reimbursement
18. Appendix
18.1. Bibliography
18.2. Report Methodology
A selection of companies mentioned in this report includes, but is not limited to:
- Flexion Taisho Pharmaceutical Bioventus Mesoblast Taiwan Liposome Company Biosplice Centrexion Therapeutics
For more information about this report visit
About ResearchAndMarkets.com
ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
Legal Disclaimer:
MENAFN provides the
information “as is” without warranty of any kind. We do not accept any
responsibility or liability for the accuracy, content, images, videos,
licenses, completeness, legality, or reliability of the information
contained in this article. If you have any complaints or copyright issues
related to this article, kindly contact the provider above.
Comments
No comment